Korlym (mifepristone) was
approved by the U.S. Food and Drug Administration to control high blood
sugar levels (hyperglycemia) in adults with endogenous Cushing’s
syndrome. This drug was approved for use in patients with endogenous
Cushing’s syndrome who have type 2 diabetes or glucose intolerance and
are not candidates for surgery or who have not responded to prior
surgery. Korlym should never be used (contraindicated) by pregnant
women....
Ref : http://www.corcept.com/medicationguide.pdf
